MENU
CARM
Stock ticker: OTC
PRICE
CHANGE
CAPITALIZATION

Carisma Therapeutics (CARM) Ownership - Who owns Carisma Therapeutics?

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
2.44M
P/E Ratio
0.31
Total Cash
N/A
Projected Growth
N/A
Total Debt
1.7M
Revenue
10.77M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
N/A
Total Debt/Equity
N/A
Revenue/Share
1.26 USD as % of share price

Fundamentals

CARM
Capitalization
N/A
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
N/A
Total Cash/Share
N/A
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
N/A
Revenue
N/A
ROE
N/A
Book Value
N/A
P/B Ratio
N/A
Cash Flow
N/A
Earnings
N/A
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
N/A
Current Ratio
N/A
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
N/A
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
N/A
Shares Held By Institutions
N/A
Shares Outstanding - Current
N/A
Total Liabilities
N/A
Total Volume MTD
N/A
Value
N/A
Gain YTD
N/A
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details